Hiwemed key facts
- Developer of vascular interventional embolization products intended to meet clinical needs.
- Notable investors include HSG (Hong Kong), Addor Capital, Jolmo Investment, Suzhou Guofa Venture Capital, Suzhou Wuzhong Jinkong Equity Investment Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Hiwemed: the Monday email on marks, rounds and moves
Hiwemed funding rounds
No funding rounds for Hiwemed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Hiwemed investors
8 investors are on record for Hiwemed, including HSG (Hong Kong), Addor Capital, Jolmo Investment and Suzhou Guofa Venture Capital.
About Hiwemed
Developer of vascular interventional embolization products intended to meet clinical needs. The company provides drug delivery products and a combination of medicine and equipment solutions for clinical use, and serves patients with cancer, uterine fibroids, prostate, osteoarthritis, etc, is positioned to develop new biomaterials and the products can be used for vascular intervention, tissue intervention, cavity intervention and other treatment methods, enabling efficient chronic tumor management for the users.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 40
- Website
- hiwemed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Hiwemed doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.